Web19 de abr. de 2004 · Children with high-risk and recurrent brain tumors currently have a poor prognosis. 1-5 To increase brain distribution of antitumor drugs that do not cross the blood-brain barrier at conventional dosages and to achieve higher concentrations within the tumor, high-dose chemotherapy (HDCT) followed by autologous hemopoietic stem cell … WebThiotepa is a chemotherapy medicine used in combination with other drugs for the treatment of certain types of cancer in children. It is also used before bone marrow transplantation or high dose therapy with stem cell rescue to help treat certain types of cancer and metabolic conditions.
Haploidentical allogeneic stem cell transplantation with post ...
Web17 de ago. de 2015 · Until today, virtually all other drugs known to cross the BBB (procarbazine, etoposide, ifosfamide, thiotepa, carmustine [BCNU], and others) have been used mostly in combination with MTX and/or Ara-C to further improve results. 26–28 As with MTX and Ara-C, most other drugs seem to be most effective at high doses, … Web11 de abr. de 2003 · High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. T Cheng 1,2, P Forsyth 2,3, A Chaudhry 1,2, D Morris 1,2, io games wormax
Thiotepa - Pharmaceutical Drugs - NCBI Bookshelf
WebPrzepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma. 1995; 17:427–33. [Abstract: 7549833] WebThiotepa and Your Skin If you are receiving “High Dose” Thiotepa (>500mg/m2), you are at risk for skin problems because the excreted drug can come through the skin in sweat. Skin problems can occur anywhere. They may be worst in the groin, armpits, creases, neck area and under dressings. Web9 de set. de 2014 · Therefore, high-dose rituximab was combined with TBC for ASCT in patients with CNS NHL. METHODS. A single-arm phase 2 trial using high-dose rituximab with cytarabine for stem cell mobilization followed by high-dose rituximab combined with thiotepa, busulfan, and cyclophosphamide (R-TBC) for ASCT was conducted. io games worm